MedChinaGo
CAR-T for Children with Relapsed B-ALL in China
November 14, 2026·Updated November 21, 2026|13 min read

CAR-T for Children with Relapsed B-ALL in China

The first paediatric CAR-T is approved. It is a bridge, not a cure.

OncologyCancer TreatmentImmunotherapyMedical TourismTreatment ComparisonWhy Choose China?

China approved its first CAR-T for children with relapsed B-ALL in November 2025. What the label covers, what the trial showed, why transplant still decides the outcome, and what the whole episode costs.

The decision is not "CAR-T or not"

When a child relapses, the conversation usually starts in the wrong place. The family is told that CAR-T exists, that it works, that it is available in China, and that it costs a fraction of what it costs at home. All of that can be true, and none of it is the decision.

The decision is what the CAR-T is for.

In a child with relapsed or refractory B-cell acute lymphoblastic leukaemia, a CD19 CAR-T is almost never the end of treatment. It is a bridge. It buys a deep, measurable remission — ideally one in which the marrow is clear at a sensitivity of one cell in ten thousand or better — and that remission is what makes the next step possible: a transplant, or, in a minority of children, a durable remission without one.

Families who arrive in China believing CAR-T replaces transplant make a different plan from the one their child's disease requires. That single misunderstanding causes more harm than the choice of product.

Why relapsed childhood B-ALL is a different problem

Acute lymphoblastic leukaemia is the most common childhood cancer, roughly three quarters of all childhood leukaemia, and B-cell disease accounts for more than 80 percent of paediatric ALL. Modern multi-agent chemotherapy cures 85 to 90 percent of children. That leaves 15 to 20 percent who relapse or never achieve remission — and that group is where the arithmetic changes sharply.

Re-induction chemotherapy in a child who has already failed several lines produces lower remission rates each time, and each attempt adds toxicity that the child carries into the next one. For decades the salvage ladder was: chemotherapy, then blinatumomab if available, then allogeneic transplant if a remission could be held long enough to get there. Blinatumomab has been approved in China for paediatric relapsed or refractory B-ALL since April 2022. It matters here twice: it is the usual bridge while CAR-T cells are made, and it is the comparator for any new salvage option.

What CD19 CAR-T changed is the remission rate at the top of that ladder. Chemotherapy in a multiply relapsed child produces remissions in a minority; CD19 CAR-T produces them in the great majority. The problem it did not solve is durability. Relapse after CAR-T remains the principal threat, which is why the transplant question is not a detail — for many children it is the whole point.

What is actually approved in China for a child

This is where most families get a surprise. China has approved several CD19 CAR-T products, but only one carries a paediatric B-ALL label.

Product (brand) Target Approved for Age List price
puzolcabtagene autoleucel (普利得凯) CD19 Relapsed or refractory CD19-positive B-ALL 3 to 21 ¥999,000
inaticabtagene autoleucel (源瑞达) CD19 Adult B-ALL; large B-cell lymphoma 18 and over ¥999,000
axicabtagene ciloleucel (奕凯达) CD19 Large B-cell lymphoma Adults ¥1,200,000
relmacabtagene autoleucel (倍诺达) CD19 Large B-cell lymphoma, follicular, mantle cell Adults ¥1,299,000

Four details in that table decide eligibility, and each one is a question to ask rather than assume.

The age band runs from 3 to 21. A two-year-old is outside the label. A nineteen-year-old is inside it — which is unusual internationally, and useful for young adults who fall between paediatric and adult services at home. The upper bound is 21, not 25 as with tisagenlecleucel in the United States and Europe.

It is a conditional approval. China's conditional pathway requires a confirmatory study to be completed after launch. That does not make the data unreliable — the pivotal trial was reviewed — but it does mean the follow-up is measured in months, not years, and the long-term curve is still being written as children are treated.

The label wording is specific about prior salvage. For a child who relapsed 12 months or more after first complete remission, the label requires salvage chemotherapy before CAR-T. This is not bureaucratic padding: late relapses are more chemosensitive, and the label is written to match the trial population.

Tisagenlecleucel has no NMPA approval in mainland China. The product used in the ELIANA trial, and the one most children in North America and Europe receive, is not available here. A Chinese centre will be offering a domestic product. Whether that matters is a fair question, and it is answered by looking at the trial data rather than at the brand.

The full set of approved products, including those for lymphoma and myeloma, is set out in the guide to every CAR-T approved in China.

Cartoon: parents and a doctor at a child's bedside, one highlighted medicine box on a tablet

The trial behind the approval, read carefully

The pivotal study was a phase 2 trial in Chinese children and young adults with relapsed or refractory CD19-positive B-ALL. The interim report at the 2024 American Society of Hematology meeting covered 64 patients; the analysis filed with China's reimbursement authority, at a median follow-up of 24.4 months, covers 84 evaluable patients. In that filing:

  • Best objective response: 97.6 percent (82 of 84)
  • Best complete response: 84.5 percent
  • MRD-negative: 98.8 percent
  • Still responding at three months: 75.0 percent
  • Median overall survival: 27.2 months, with 52.1 percent alive at two years
  • Grade 3 or higher CRS: 27.0 percent; grade 3 or higher ICANS: 39.3 percent

Read that list twice. The first number is the one that appears in press releases, and it is real: nearly every child who received the cells responded at some point. The numbers underneath decide what the treatment is worth to your child. A response at three months in three quarters of patients, and a median survival of a little over two years, is a genuine advance for a group that had already failed several lines of therapy. It is not a cure, and it is not a replacement for what comes next.

Measure pCAR-19B (China) Tisagenlecleucel (ELIANA)
Patients treated 84 evaluable 75
Best response 97.6% 81%
Complete response 84.5% 81% (CR/CRi)
MRD-negative 98.8% Most responders
Responding at 3 months 75.0% 81%
Median follow-up 24.4 months 13.1 months
Median overall survival 27.2 months Not reached
Grade 3+ CRS 27.0% 46%
Grade 3+ ICANS 39.3% 13%

Two cautions before you read that table as a ranking. It is a single-arm study, so nothing in it is evidence of superiority over another product. And the ELIANA population was treated in 2015 to 2017 across several countries, with different prior therapy, bridging and MRD assays. The table orients you; it cannot predict your child's outcome.

MRD is the number that decides everything

Minimal residual disease is the measure of what is left after treatment, counted at a sensitivity of one leukaemia cell in ten thousand (10⁻⁴) or, with newer methods, one in a million. In paediatric B-ALL it is the single most predictive number in the entire pathway, and after CAR-T it is the number that tells you whether the bridge is holding.

A complete remission with a positive MRD is not the same result as a complete remission with an undetectable MRD, even though both are called remission on a discharge summary. The first predicts early relapse. The second is what makes a transplant worth doing.

Three practical consequences follow.

Ask which assay and which sensitivity. Flow cytometry at 10⁻⁴ and next-generation sequencing at 10⁻⁶ are different tests with different implications. A report that says "MRD negative" without stating the method is not a result you can act on.

Do not accept "we will watch it" after a positive MRD at day 28. In a child, that is time spent while the clone regrows. The options are a second CAR-T against a different target, blinatumomab, or moving the transplant earlier. All three are decisions, and all three are better made in week four than in month four.

Then transplant, or not?

This is the argument that divides haematologists, and families are usually told only one side of it.

The case for transplant after CAR-T is that CAR-T-induced remission is often temporary in high-risk disease. A 2026 analysis from a Chinese paediatric centre followed children who achieved remission after CAR-T and found a four-year survival of 75 percent in those who went on to allogeneic transplant against 24 percent in those who did not. The difference is large and points in one direction, but the analysis is small and the result did not reach conventional statistical significance (P = 0.067). It is evidence of a pattern, not proof of a rule.

The case for stopping at CAR-T is that transplant carries its own mortality, chronic graft-versus-host disease and a long shadow over a childhood. For a child with a late relapse, favourable genetics and a sustained MRD-negative remission, some centres now discuss observation instead of transplant. That conversation is legitimate — but it belongs after the CAR-T, because the MRD result is what decides it.

What is not legitimate is arriving at a Chinese centre with a high-risk child — Ph-positive, Ph-like, KMT2A-rearranged, TP53-mutated, or relapsed within 18 months of diagnosis — and being told that CAR-T alone will be enough, without a donor search having started.

Situation Usual plan after CAR-T
Early relapse, high-risk genetics, MRD-negative Allogeneic transplant, donor search started before infusion
Late relapse, standard-risk genetics, sustained MRD-negative Transplant or observation, decided at 3 months
MRD-positive at day 28 Second CAR-T, blinatumomab, or expedited transplant
No suitable donor or transplant contraindicated CAR-T alone, with maintenance strategy and close MRD monitoring

The practical point is timing. A donor search takes six to ten weeks. If it starts after the CAR-T result, the child may be in relapse before a graft is available. In China, haploidentical transplant — using a parent as donor — is routine, which widens the options for families without a matched sibling.

The four to six weeks nobody plans for

From apheresis to infusion, a CAR-T cycle takes roughly four to six weeks: collection, manufacture, lymphodepletion, infusion. In a child whose blast count is doubling every week, that window is the risk.

Bridging therapy is what holds the disease during the wait, and the choice is not neutral. Blinatumomab is the most effective bridge in CD19-positive disease, but it is also a CD19-directed therapy, and using it immediately before a CD19 CAR-T is a sequencing decision that some protocols restrict. Low-intensity chemotherapy is gentler on T-cell fitness but less effective at control.

The order of steps, and what can be done remotely before you fly, is set out in the patient journey guide. One thing worth knowing before you book flights: a child must be fit enough to travel and to wait. Flying a child in active blast crisis across time zones, to begin a six-week process, is a risk that needs to be discussed with the treating team at home, not decided by a family in a travel agency's office.

Cartoon: four weeks crossed off a calendar while a cell vial travels to a hospital bed

What actually goes wrong

Cytokine release syndrome. Fever is near-universal and expected. Severe CRS is less common in children than in adults but it is not rare — 46 percent of patients had grade 3 or higher CRS in ELIANA, and 27 percent in the Chinese filing. The single most important question to ask a Chinese centre is whether tocilizumab is stocked on site and whether it can be given within an hour. If the answer is vague, walk away.

ICANS. The Chinese filing reports grade 3 or higher neurotoxicity in 39.3 percent of patients — well above the 13 percent seen in ELIANA — so this is not a theoretical risk. A child with ICANS needs paediatric intensive care, not an adult ward with a spare bed. Ask who covers at night.

B-cell aplasia and low immunoglobulin. Most children need monthly intravenous immunoglobulin for months to years after CD19 CAR-T. This is a real cost and a real logistics problem for a family that returns home: the supply, the infusion schedule and the funding all have to be arranged before discharge, not after.

Infection. The leading cause of treatment-related death in the first three months.

CD19-negative relapse. The characteristic failure mode of CD19 CAR-T. A large share of relapses after CD19-directed therapy come back with the antigen gone, which is why the second attempt needs a different target.

The long tail. Second malignancies, fertility, growth and neurocognitive follow-up. A child treated at five needs to be followed at fifteen — ask what the long-term programme consists of.

If CD19 disappears: the second attempt

A CD19-negative relapse is not the end of the road, but it is the end of that one. Repeating the same target rarely works, and Chinese centres treat a high volume of relapsed leukaemia.

CD22-directed CAR-T. The most established alternative target in B-ALL, available in China mainly through trials.

Dual-target CAR-T. Products engaging CD19 and CD22 simultaneously, designed to reduce antigen escape. Several are in clinical trials in China.

Donor-derived CAR-T after transplant. For a child who relapses after transplant, cells from the original donor can be engineered, avoiding a second collection.

Blinatumomab re-challenge and second transplant. Less effective after CD19 loss, but still part of the ladder.

Trials are the realistic route, and China's density of them is the strongest argument for coming here in the relapsed setting. Ask whether the drug is sponsor-covered, whether screening can be done in English, and which prior therapies exclude the child.

What it costs, honestly

The published list price of the paediatric product is ¥999,000. That is the price of the cells, not of the treatment.

Item Typical range (CNY) Notes
CAR-T product 999,000 Published list price
Screening and workup 30,000 to 60,000 Marrow, imaging, cardiac, infection
Apheresis and cryopreservation 20,000 to 40,000 Sometimes bundled
Bridging therapy 30,000 to 150,000 Blinatumomab at the top of the range
Monitoring and ICU 50,000 to 150,000 14 to 21 days, more if CRS is severe
Complication management Variable Infection and ICU stay drive this
CAR-T episode total 1.3 to 1.7 million Before transplant

That is arithmetic on component prices, not a hospital quote: no Chinese centre publishes a bundled episode price. Add a further 250,000 to 450,000 for an allogeneic transplant if one follows, and the honest total for a high-risk child is somewhere between 1.5 and 2.2 million yuan.

None of the CAR-T products is in China's national reimbursement list. Provincial supplementary schemes and commercial policies cover some of it, but a foreign family should assume cash, paid before or during treatment, with a deposit at admission. The structure of these costs is set out in the cost comparison.

Insist on an itemised written quote rather than a package figure, and a written statement of what happens financially if the child spends three weeks in intensive care.

Cartoon: family reviewing an itemised hospital bill with a calculator and an advisor

Who should not come

A child under three. Outside the label. Trials or another country.

A child with uncontrolled infection or organ failure. CAR-T is not a rescue for a child who would not survive lymphodepletion.

No caregiver who can stay three months. The monitoring period, the complication window and the transplant decision all need an adult present who is not the patient.

An expectation that CAR-T replaces transplant in a high-risk child. If that is the plan, the plan is wrong.

A budget that covers the product but not the complications. A partially funded episode forces decisions — stopping monitoring early, flying home at day 14 — at exactly the wrong moment.

Ten questions to ask before you book

  1. Is my child inside your approved label, or is this a trial?
  2. What is your MRD-negative rate at day 28, and by which assay?
  3. How many of your paediatric patients went on to transplant?
  4. Is tocilizumab stocked on site, and how quickly can it be given?
  5. Who provides paediatric intensive care at night?
  6. What is the itemised total cost, including complications?
  7. What is the bridging plan while the cells are being manufactured?
  8. Has a donor search started, and is haploidentical transplant available here?
  9. What is the long-term follow-up programme, and will you share data with our paediatrician at home?
  10. What happens if the disease progresses during manufacturing?

A centre that answers all ten in writing is a centre worth travelling to. A centre that answers three and deflects the rest is not, however impressive its corridor.

How to start

Send records before you ask about price. A Chinese centre can tell you in days whether your child is inside the label, whether a trial fits better and what the realistic sequence is — but only if it sees the documents: diagnosis and immunophenotype, cytogenetics and FISH, every MRD result with its date and method, a line-by-line treatment table with responses, current counts, the infection screen and the cardiac echo.

If the disease returned after an earlier CAR-T, what to do after relapse is the place to start; if you are still deciding whether cell therapy is the right route, CAR-T against transplant and chemotherapy sets out the comparison.

When you are ready, the CAR-T programme in China explains what we review, what we will not promise, and how the first two weeks run.

Frequently Asked Questions

Author

M

MedChinaGo Medical Team

Medical Tourism Specialists

https://www.chinamedicaltrips.com/about

This information is for educational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider for personal medical decisions.

Ready to Start Your Medical Journey?

Contact us today for a free consultation and personalized treatment plan

Free Consultation